$AVTE
Aerovate Therapeutics, Inc. Stock $avte

$avte Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000149315222022598 Filed on August 15, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.369M	$3.852M	$3.764M
YoY Change	21.1%	89.66%	544.52%
% of Gross Profit
Research & Development	$10.78M	$8.363M	$7.255M
YoY Change	215.48%	93.27%	230.37%
% of Gross Profit
Depreciation & Amortization	$20.00K	$17.00K	$11.00K
YoY Change	566.67%	750.0%	450.0%
% of Gross Profit
Operating Expenses	$14.15M	$12.22M	$11.02M
YoY Change	128.26%	111.55%	296.37%
Operating Profit	-$14.15M	-$12.22M	-$11.02M
YoY Change	128.26%	111.55%
Interest Expense	$560.0K	$230.0K	$109.0K
YoY Change	3400.0%	11400.0%
% of Operating Profit
Other Income/Expense, Net	$564.0K	$224.0K	$0.00
YoY Change		-22500.0%	-100.0%
Pretax Income	-$13.59M	-$11.99M	-$10.91M
YoY Change	119.73%	40.15%	292.3%
Income Tax
% Of Pretax Income
Net Earnings	-$13.59M	-$11.99M	-$10.91M
YoY Change	119.73%	107.64%	292.3%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.56	-$0.49	-$0.45
Diluted Earnings Per Share	-$0.56	-$491.2K	-$446.9K
COMMON SHARES
Basic Shares Outstanding	24.45M shares	24.41M shares	24.41M
Diluted Shares Outstanding	24.45M	24.41M	24.41M

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$142.6M	$152.0M	$161.1M
YoY Change	-21.17%	156.95%	1764.04%
Cash & Equivalents	$22.42M	$27.46M	$28.14M
Short-Term Investments	$120.2M	$124.5M	$132.9M
Other Short-Term Assets	$2.578M	$1.461M	$4.813M
YoY Change	15.92%	818.87%	399.79%
Inventory
Prepaid Expenses	$2.115M	$415.0K
Receivables
Other Receivables
Total Short-Term Assets	$145.2M	$153.4M	$165.9M
YoY Change	-20.72%	158.73%	1627.25%
LONG-TERM ASSETS
Property, Plant & Equipment	$330.0K	$316.0K	$787.0K
YoY Change	-55.7%	802.86%	2027.03%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.076M	$731.0K	$327.0K
YoY Change	287.05%	-76.34%	6.51%
Total Long-Term Assets	$2.500M	$2.235M	$1.114M
YoY Change	144.38%	-28.48%	223.84%
TOTAL ASSETS
Total Short-Term Assets	$145.2M	$153.4M	$165.9M
Total Long-Term Assets	$2.500M	$2.235M	$1.114M
Total Assets	$147.7M	$155.7M	$167.0M
YoY Change	-19.81%	149.36%	1578.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.541M	$2.068M	$2.863M
YoY Change	77.73%	-32.02%	84.71%
Accrued Expenses	$2.910M	$1.537M	$1.599M
YoY Change	166.97%	49.08%	699.5%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.705M	$3.756M	$4.703M
YoY Change	101.44%	-10.42%	163.92%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$813.0K	$875.0K	$349.0K
YoY Change	79.87%	-38143.48%
Total Long-Term Liabilities	$813.0K	$875.0K	$349.0K
YoY Change	79.87%	-38143.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.705M	$3.756M	$4.703M
Total Long-Term Liabilities	$813.0K	$875.0K	$349.0K
Total Liabilities	$8.518M	$4.631M	$5.052M
YoY Change	99.16%	10.51%	183.5%
SHAREHOLDERS EQUITY
Retained Earnings	-$72.88M	-$59.29M
YoY Change		169.7%
Common Stock	$2.000K	$2.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$139.1M	$151.1M	$161.9M
YoY Change
Total Liabilities & Shareholders Equity	$147.7M	$155.7M	$167.0M
YoY Change	-19.81%	149.36%	1578.72%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$13.59M	-$11.99M	-$10.91M
YoY Change	119.73%	107.64%	292.3%
Depreciation, Depletion And Amortization	$20.00K	$17.00K	$11.00K
YoY Change	566.67%	750.0%	450.0%
Cash From Operating Activities	-$9.720M	-$8.876M	-$5.661M
YoY Change	48.94%	121.62%	49.96%
INVESTING ACTIVITIES
Capital Expenditures	-$33.00K	-$130.0K	-$28.00K
YoY Change	-41.07%		-30.0%
Acquisitions
YoY Change
Other Investing Activities	$4.678M	$8.324M	-$20.37M
YoY Change
Cash From Investing Activities	$4.645M	$8.194M	-$20.40M
YoY Change	-8394.64%		50897.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	37.00K	2.000K
YoY Change	-99.97%	-100.0%
NET CHANGE
Cash From Operating Activities	-9.720M	-8.876M	-5.661M
Cash From Investing Activities	4.645M	8.194M	-20.40M
Cash From Financing Activities	37.00K	2.000K
Net Change In Cash	-5.038M	-680.0K	$0.00
YoY Change	-104.14%	-101.35%	-100.0%
FREE CASH FLOW
Cash From Operating Activities	-$9.720M	-$8.876M	-$5.661M
Capital Expenditures	-$33.00K	-$130.0K	-$28.00K
Free Cash Flow	-$9.687M	-$8.746M	-$5.633M
YoY Change	49.72%	118.38%	50.82%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q2	us-gaap	Debt Securities Trading Unrealized Loss DebtSecuritiesTradingUnrealizedLoss		usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
	us-gaap	Debt Securities Trading Unrealized Loss DebtSecuritiesTradingUnrealizedLoss		usd
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001798749
	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2021Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2021Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
	AVTE	Accretion Of Discounts And Amortization Of Premiums On Investments Net AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet		usd
	AVTE	Increase Decrease In Operating Lease Asseta And Liability IncreaseDecreaseInOperatingLeaseAssetaAndLiability		usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments		usd
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments		usd
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock		usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
	us-gaap	Available For Sale Debt Securities Gross Unrealized Gain AvailableForSaleDebtSecuritiesGrossUnrealizedGain		usd
	us-gaap	Operating Lease Payments OperatingLeasePayments		usd
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost		usd
	us-gaap	Operating Lease Cost OperatingLeaseCost		usd
CY2021Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost		usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost		usd
CY2021Q2	us-gaap	Lease Cost LeaseCost		usd
	us-gaap	Lease Cost LeaseCost		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40544
	dei	Entity Registrant Name EntityRegistrantName	AEROVATE THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-1377888
	dei	Entity Address Address Line1 EntityAddressAddressLine1	930 Winter Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite M-500
	dei	Entity Address City Or Town EntityAddressCityOrTown	Waltham
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02451
	dei	City Area Code CityAreaCode	(617)
	dei	Local Phone Number LocalPhoneNumber	443-2400
	dei	Security12b Title Security12bTitle	Common stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	AVTE
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24418434	shares
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	24448144	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27457000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54197000	usd
CY2022Q2	us-gaap	Short Term Investments ShortTermInvestments	124531000	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	113178000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1461000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6958000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	153449000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	174333000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	316000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	186000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1188000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	542000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	731000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	302000	usd
CY2022Q2	us-gaap	Assets Assets	155684000	usd
CY2021Q4	us-gaap	Assets Assets	175363000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2068000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1208000	usd
CY2022Q2	AVTE	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	1341000	usd
CY2021Q4	AVTE	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	1150000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	347000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	192000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3756000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2550000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	862000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	382000	usd
CY2022Q2	us-gaap	Other Liabilities OtherLiabilities	13000	usd
CY2021Q4	us-gaap	Other Liabilities OtherLiabilities	13000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	4631000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	2945000	usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24418434	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24410393	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24410393	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	211129000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	208867000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-785000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-59000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-59293000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-36392000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	151053000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	172418000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	155684000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	175363000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8363000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4327000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15618000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6523000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3852000	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1447000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7615000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2031000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	12215000	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	5774000	usd
	us-gaap	Operating Expenses OperatingExpenses	23233000	usd
	us-gaap	Operating Expenses OperatingExpenses	8554000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-12215000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5774000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-23233000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8554000	usd
CY2022Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	230000	usd
CY2021Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	2000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	338000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	2000	usd
CY2022Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	6000	usd
CY2021Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	3000	usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	6000	usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	4000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	224000	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	332000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-11991000	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-5775000	usd
	us-gaap	Profit Loss ProfitLoss	-22901000	usd
	us-gaap	Profit Loss ProfitLoss	-8556000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-11991000	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-5775000	usd
	us-gaap	Profit Loss ProfitLoss	-22901000	usd
	us-gaap	Profit Loss ProfitLoss	-8556000	usd
CY2022Q2	us-gaap	Debt Securities Trading Unrealized Loss DebtSecuritiesTradingUnrealizedLoss	141000	usd
	us-gaap	Debt Securities Trading Unrealized Loss DebtSecuritiesTradingUnrealizedLoss	726000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12132000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5775000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23627000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8556000	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.49
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-23.80
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.94
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-35.29
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24410503	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	243076	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24410448	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	243076	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	172418000	usd
CY2022Q1	us-gaap	Debt Securities Trading Unrealized Loss DebtSecuritiesTradingUnrealizedLoss	585000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1024000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-10910000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	161947000	usd
CY2022Q2	us-gaap	Debt Securities Trading Unrealized Loss DebtSecuritiesTradingUnrealizedLoss	141000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1224000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	14000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-11991000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	151053000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-13344000	usd
CY2021Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	-13000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-2781000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-16115000	usd
CY2021Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	-9000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	321000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-5775000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-21578000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-22901000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8556000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2248000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	344000	usd
	us-gaap	Depreciation Depreciation	28000	usd
	us-gaap	Depreciation Depreciation	4000	usd
	AVTE	Accretion Of Discounts And Amortization Of Premiums On Investments Net AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet	-32000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-5493000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	56000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	428000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	74000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	875000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	563000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	191000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-5000	usd
	AVTE	Increase Decrease In Operating Lease Asseta And Liability IncreaseDecreaseInOperatingLeaseAssetaAndLiability	-11000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14537000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7780000	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	71791000	usd
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	59744000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	158000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	40000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-12205000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-40000	usd
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	63512000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1115000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	62397000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-26740000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	54577000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	54197000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4573000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	27457000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	59150000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	765000	usd
	AVTE	Deferred Offering Costs Included In Accounts Payable DeferredOfferingCostsIncludedInAccountsPayable	1000	usd
	AVTE	Deferred Offering Costs Included In Accounts Payable DeferredOfferingCostsIncludedInAccountsPayable	1901000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	152000000.0	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	113237000	usd
CY2021	us-gaap	Available For Sale Debt Securities Gross Unrealized Gain AvailableForSaleDebtSecuritiesGrossUnrealizedGain	9000	usd
CY2021Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-3.1060103 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding common stock. Accordingly, the conversion ratio for the Company’s outstanding convertible preferred stock was proportionately adjusted such that the common stock issuable upon conversion of such preferred stock was decreased in proportion to the Reverse Stock Split. The par value of the common stock was not adjusted as a result of the Reverse Stock Split. All references to common stock, options to purchase common stock, early exercised options, share data, per share data, convertible preferred stock (to the extent presented on an as-converted to common stock basis) and related information contained in these financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented.
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_zQwAqsFntQ05" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(c)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zpLjrTQm58Ob">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the Company’s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations, and financial condition will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, as well as the economic impact on local, regional, national and international markets. Actual results could differ materially from those estimates. Accounting estimates and management judgements reflected in the consolidated financial statements include: normal recurring accruals, including the accrual for research and development expenses, stock-based compensation and fair value of investments. Estimates and assumptions are reviewed quarterly. Any revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-11991000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-5775000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-22901000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8556000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11991000	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5784000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22901000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8578000	usd
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24410503	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	243076	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24410448	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	243076	shares
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.49
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-23.80
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.94
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-35.29
CY2021	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	68000	usd
CY2021	us-gaap	Debt Securities Available For Sale Gain Loss DebtSecuritiesAvailableForSaleGainLoss	113178000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P9Y7D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	31633000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.73
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3955021	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16953808	shares
CY2022Q2	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	16286000	usd
CY2022Q2	AVTE	Commercial Paper Carrying Value CommercialPaperCarryingValue	5991000	usd
CY2022Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	22277000	usd
CY2022Q2	us-gaap	Us Government Securities At Carrying Value USGovernmentSecuritiesAtCarryingValue	32147000	usd
CY2022Q2	AVTE	Corporate Debt Securities CorporateDebtSecurities	1991000	usd
CY2022Q2	AVTE	Commercial Paper Short Term Investment CommercialPaperShortTermInvestment	84905000	usd
CY2022Q2	AVTE	Agency Bond Short Term Investment AgencyBondShortTermInvestment	5488000	usd
CY2022Q2	us-gaap	Short Term Investments ShortTermInvestments	124531000	usd
CY2022Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	146808000	usd
CY2021Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	39653000	usd
CY2021Q4	AVTE	Commercial Paper Carrying Value CommercialPaperCarryingValue	14448000	usd
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	54101000	usd
CY2021Q4	us-gaap	Us Government Securities At Carrying Value USGovernmentSecuritiesAtCarryingValue	25135000	usd
CY2021Q4	AVTE	Corporate Debt Securities CorporateDebtSecurities	10715000	usd
CY2021Q4	AVTE	Commercial Paper Short Term Investment CommercialPaperShortTermInvestment	77328000	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	113178000	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	167279000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	125316000	usd
	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	785000	usd
	us-gaap	Debt Securities Available For Sale Gain Loss DebtSecuritiesAvailableForSaleGainLoss	124531000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.765	pure
CY2022Q2	AVTE	Prepaid Research And Development PrepaidResearchAndDevelopment	820000	usd
CY2021Q4	AVTE	Prepaid Research And Development PrepaidResearchAndDevelopment	5233000	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	415000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1485000	usd
CY2022Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	226000	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	240000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1461000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6958000	usd
CY2022Q2	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	817000	usd
CY2021Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	790000	usd
CY2022Q2	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	373000	usd
CY2021Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	217000	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	151000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	143000	usd
CY2022Q2	AVTE	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	1341000	usd
CY2021Q4	AVTE	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	1150000	usd
	us-gaap	Lease Cost LeaseCost	188000	usd
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.738	pure
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.765	pure
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.687	pure
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.696	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.736	pure
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	147000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	449000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	489000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	242000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1327000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	118000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1209000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	347000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	862000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1209000	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.06	pure
	us-gaap	Operating Lease Payments OperatingLeasePayments	113000	usd
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	92000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	142000	usd
CY2022Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	11000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	46000	usd
CY2022Q2	us-gaap	Lease Cost LeaseCost	103000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3953390	shares
CY2022Q2	AVTE	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Exercise ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForExercise	1552307	shares
CY2022Q2	AVTE	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Vesting ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForVesting	1631	shares
CY2022Q2	us-gaap	Deferred Compensation Arrangement With Individual Common Stock Reserved For Future Issuance DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance	230000	shares
CY2022Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	5737328	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3454374	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.85
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y5M1D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	19378000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	507057	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	13.08
	AVTE	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P9Y9M14D
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	8041000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.74
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3953390	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.66
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y7D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	31633000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	875657	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	5.91
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P8Y9M18D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	8533000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3953390000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	7.66
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.687	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.696	pure
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.025	pure
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.034	pure
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.010	pure
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.012	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.016	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.034	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.010	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.012	pure
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1224000	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	321000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2248000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	344000	usd

Files In Submission

Name	View Source	Status
0001493152-22-022598-index-headers.html	Edgar Link	pending
0001493152-22-022598-index.html	Edgar Link	pending
0001493152-22-022598.txt	Edgar Link	pending
0001493152-22-022598-xbrl.zip	Edgar Link	pending
avte-20220630.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
avte-20220630_def.xml	Edgar Link	unprocessable
avte-20220630_cal.xml	Edgar Link	unprocessable
avte-20220630_lab.xml	Edgar Link	unprocessable
avte-20220630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVTE
Aerovate Therapeutics, Inc. Stock $avte

2022 Q3 Form 10-Q Financial Statement

#000149315222022598 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVTE Aerovate Therapeutics, Inc. Stock $avte

2022 Q3 Form 10-Q Financial Statement

#000149315222022598 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVTE
Aerovate Therapeutics, Inc. Stock $avte